BioSpace News Archive

Kallyope, Inc. today announced the initiation of their Phase 2 trial evaluating K-757 and K-833.

Deep Genomics announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.

Precision BioSciences, Inc. today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.”

Can-Fite BioPharma Ltd today announced that its study titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via De-regulation of the Wnt/β-catenin Signaling Pathway” has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer, held from September 27-30, 2023, in Boston, Massachusetts.

Theralase® announced that it has successfully completed its non-Good Laboratory Practices (“GLP”) preclinical toxicology analysis of Rutherrin® for Glio Blastoma Multiforme (“GBM”). GBM is the most aggressive and most common type of brain cancer.

Biomind Labs Inc. provides a corporate update outlining its research and development, intellectual property and clinical trials initiatives.

PharmaTher Holdings Ltd. today announced the U.S. Food and Drug Administration (“FDA”) has accepted the Abbreviated New Drug Application (“ANDA”) for KETARX.

Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in the combination therapy arm of the Phase 1/2 clinical trial for SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.

Coeptis Therapeutics Holdings, Inc. today announced that Colleen Delaney, MD, MSc, Chief Scientific and Medical Officer, will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.